ABVX abivax.com: Net earnings per share for the last 12 months

Critical risks of failed final drug trials and revenue deficits serve as the primary drivers for ABIVAX (ABVX). This chart of net income per share YoY ttm visualizes these fluctuations, where -101.40 reflects the latest value of the metric. Development relies on partnerships with scientific centers, yet the success of the entire ecosystem depends entirely on FDA and EMA verdicts.
ABIVAX - analytical breakdowns and key metrics (ABVX)

This indicator measures the annual change in earnings per share over the last 12 months, allowing for an assessment of the growth or decline rates of the business's actual profitability. By analyzing the YoY ttm net income per share chart, an investor can identify valuation overheating, which is critical for ABIVAX (ABVX), whose model is based on capital burn without the presence of commercial products.